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Objective: Bacterial infection contributes to diverse noninfectious diseases and worsens outcome after stroke. Strep-
tococcus pneumoniae, the most common infection in patients at risk of stroke, is a major cause of prolonged hospi-
talization and death of stroke patients, but how infection impacts clinical outcome is not known.
Methods: We induced sustained pulmonary infection by a human S. pneumoniae isolate in naive and comorbid
rodents to investigate the effect of infection on vascular and inflammatory responses prior to and after cerebral
ischemia.
Results: S. pneumoniae infection triggered atherogenesis, led to systemic induction of interleukin (IL) 1, and pro-
foundly exacerbated (50–90%) ischemic brain injury in rats and mice, a response that was more severe in combination
with old age and atherosclerosis. Systemic blockade of IL-1 with IL-1 receptor antagonist (IL-1Ra) fully reversed
infection-induced exacerbation of brain injury and functional impairment caused by cerebral ischemia. We show that
infection-induced systemic inflammation mediates its effects via increasing platelet activation and microvascular coag-
ulation in the brain after cerebral ischemia, as confirmed by reduced brain injury in response to blockade of platelet
glycoprotein (GP) Iba. IL-1 and platelet-mediated signals converge on microglia, as both IL-1Ra and GPIba blockade
reversed the production of IL-1a by microglia in response to cerebral ischemia in infected animals.
Interpretation: S. pneumoniae infection augments atherosclerosis and exacerbates ischemic brain injury via IL-1 and
platelet-mediated systemic inflammation. These mechanisms may contribute to diverse cardio- and cerebrovascular
pathologies in humans.
ANN NEUROL 2014;75:670–683
Community-acquired pneumonia is a common conditionthat leads to prolonged hospitalization, impaired clinical
outcome, and increased mortality of patients, especially those
with compromised immunity, such as children, the elderly,
and those with immune suppression as a result of disease or
injury.1,2 The gram-positive bacterium Streptococcus pneumo-
niae is a major human pathogen, and the most common
cause of bacterial community-acquired pneumonia.3
Infection also contributes to the development of
cardio- and cerebrovascular diseases and is associated
with poor outcomes after heart disease and stroke.4–8 S.
pneumoniae infection could contribute to stroke or cardi-
oembolism by triggering the rupture of an atherosclerotic
plaque in humans,7–10 and molecular signatures of com-
mon bacteria, including Streptococcus species, have been
identified in atherosclerotic lesions.11,12 Vaccination
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against S. pneumoniae reduces atherosclerosis; however,
the effect of S. pneumoniae infection on atherogenesis has
not been demonstrated experimentally.
Infection is a key risk factor for stroke in young
patients,5 a cohort without any atherosclerotic burden,
suggesting that infection could contribute to an ischemic
event independently of inducing plaque rupture. Clinical
data indicate that S. pneumoniae, together with other
common infections such as Chlamydia pneumoniae and
Haemophilus influenzae, also contributes to impaired out-
come, prolonged hospitalization, and death after stroke.5
Experimental stroke in mice propagates pneumonia.13,14
However, it is not known if sustained bacterial infections
preceding an acute cerebrovascular event could trigger
stroke or contribute to increased stroke pathophysiology.
Therefore, the main hypothesis tested in the study was
whether preceding infection by a clinically highly relevant
bacterial strain, S. pneumoniae, induces systemic vascular
inflammation and worsens stroke outcome and whether
this occurs via inflammatory mechanisms that could be
blocked therapeutically.
Here we demonstrate that S. pneumoniae infection
promotes atherogenesis, and exacerbates inflammatory
responses to cerebral ischemia, leading to increased brain
injury via platelets and interleukin (IL) 1. Thus, we sug-
gest that complications after acute vascular events is pre-
ceded by a rapid systemic inflammatory response and
excessive coagulation induced by pre-existing infection that
profoundly impairs outcome. This could be prevented by
treatment with IL-1 receptor antagonist (IL-1Ra).
Materials and Methods
Animals
Experiments were carried out in adult male wild-type (WT;
C57BL/6J; Harlan-Olac, Blackthorn, UK) and ApoE2/2 (JAX
2052; Jackson Laboratory, Bar Harbor, ME) mice, aged 12 to
20 weeks. Male Wistar rats were 8 weeks old (250–300g). Aged
(15 months) lean and (JCR:LA-cp; cp/cp) corpulent rats, which
are obese, atherosclerotic, and insulin resistant,15 were also
used. Animals were allowed free access to food and water and
maintained under temperature-, humidity-, and light-controlled
conditions. All animal procedures adhered to the UK Animals
(Scientific Procedures) Act (1986), and experiments were per-
formed in accordance with STAIR and ARRIVE guidelines.
Infection with S. pneumoniae
A protocol for doses and timing of S. pneumoniae (American
Type Culture Collection [ATCC] 49619, capsular serotype 19F
[Danish]) challenge was established to allow low-grade, indolent
pulmonary exposure to S. pneumoniae infection that is sustained
in animals for a period of 6 to 7 days. Animals were lightly
anesthetized with 2.5% isoflurane, and S. pneumoniae or
phosphate-buffered saline (PBS; mock infection, 50ll, pH 7.4)
was slowly pipetted onto the nostrils to allow subsequent dis-
semination throughout the lungs. An ascending infectious chal-
lenge was used on day 0 (2 3 108cfu/ml), day 2 (4 3 108cfu/
ml), and day 5 (8 3 108cfu/ml). Mild piloerection and slightly
increased respiration rate were observed after infection in 30%
of the animals, but none of the infected mice showed any neu-
rological symptoms, including signs of meningitis, intracranial
hemorrhage, or visible neuronal injury in the absence of experi-
mental stroke. Animals showing signs of more severe infection,
such as markedly reduced activity, weight loss, or a hunched
appearance were excluded from further experiments (3 mice, 0
rats). Blood pH, pCO2, pO2, and O2 saturation were analyzed
with a 248 Blood Gas Analyser (Siemens Healthcare Diagnos-
tics, Surrey, UK).
Middle Cerebral Artery Occlusion
Middle cerebral artery occlusion (MCAo) was performed using
the intraluminal filament technique as described earlier16 on
mice infected with S. pneumoniae and age/weight-matched con-
trols weighing 25 to 30g. In brief, animals were anesthetized
with isoflurane and a silicone-coated monofilament (210lm tip
diameter; Doccol, Redlands, CA) was introduced into the left
external carotid artery and advanced along the internal carotid
artery to occlude the MCA for 30 minutes. Occlusion was con-
firmed by a laser Doppler (Moor Instruments, Axminster, UK).
During surgery, core temperature was maintained at
376 0.5C. Due to the large size and multiple comorbidities
of corpulent rats, a distal MCAo model was used in all rat
experiments to avoid extensive tissue dissection and mortality.
Rats were anesthetized with isoflurane and subjected to cerebral
ischemia by transient occlusion of the distal MCA for 60
minutes using a 10-0 suture as described earlier.17 After experi-
mental stroke, 3 mice and 2 rats were excluded pre hoc due to
improper occlusion of the MCA (n5 2) and surgical artifacts
(n5 3).
Experimental Design
To investigate whether S. pneumoniae infection contributes to
atherogenesis or vascular inflammation in different vascular
beds, ApoE2/2 and C57BL/6J mice aged 12 weeks were fed
either an atherogenic Paigen diet (18.5% fat, 0.9% cholesterol,
0.5% cholate, 0.26% sodium; Special Diet Services, Witham,
UK) or a normal chow diet (4.3% fat, 0.02% cholesterol; Spe-
cial Diet Services) for 8 weeks prior to mock infection or infec-
tion with S. pneumoniae (8 experimental groups). Corpulent
rats that spontaneously develop atherosclerosis as they age15
were fed a chow diet throughout. Mice and rats were sacrificed
6 or 7 days after the first infection, respectively.
For the experiments investigating how S. pneumoniae infec-
tion preceding experimental stroke influences outcome, all ani-
mals were fed a chow diet. Naive male C57BL/6J mice aged 14
to 16 weeks were infected with S. pneumoniae on day 0, day 2,
and day 5 followed by 30 minutes of MCAo16 on day 6 and 4
hours or 24 hours of reperfusion. In separate experiments, mice
were treated intraperitoneally with a single bolus of recombinant
IL-1Ra (100mg/kg; Biovitrium, Stockholm, Sweden) or placebo
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(0.5% bovine serum albumin in PBS, pH 7.4). To block platelet
adhesion through glycoprotein (GP) Iba, mice received 100lg
anti-GPIba Fab (p0p/B),18 or control immunoglobulin (Ig) G
intravenously. IL-1Ra or anti-GPIba was administered 1 hour
after 30-minute MCAo, and mice were euthanized at 24-hour
reperfusion.
Aged lean and (JCR:LA-cp; cp/cp) corpulent rats or young
Wistar rats were mock infected/infected with S. pneumoniae on
day 0, day 2, and day 5 followed by 60 minutes of transient dis-
tal MCAo17 on day 7 and 24 hours of reperfusion. A group of
Wistar rats received a single dose of IL-1Ra (100mg/kg) or pla-
cebo subcutaneously at 1 hour of reperfusion.
Tissue Processing
Under terminal anesthesia, blood was taken from the heart
using 3.8% sodium citrate (1:10) as an anticoagulant. Animals
were then perfused transcardially with saline followed by para-
formaldehyde (PFA; 4% in PBS; Sigma-Aldrich, Dorset, UK).
Brains were postfixed in 4% PFA at 4C for 24 hours, and cry-
oprotected in sucrose/PBS. Coronal brain sections (20lm thick
for mice and 30lm thick for rats) were cut on a sledge micro-
tome (Bright series 8000; Bright Instruments, Huntingdon,
UK). For cytokine measurement, saline-perfused brain, lung,
spleen, and liver samples were homogenized, and processed as
described earlier.19 Except for the lungs, S. Pneumoniae was not
recovered from any other tissues examined, as expected in the
case of the ATCC 49619 strain.
Measurement of Infarct Volume and Blood–
Brain Barrier Damage
The volume of ischemic and blood–brain barrier (BBB) damage
was measured as described previously and corrected for
edema.16 Leakage of plasma-derived IgG (BBB damage) was
detected with biotinylated horse antimouse IgG (1:500; Vector
Laboratories, Burlingame, CA) followed by incubation with
ABC solution (1:500; Vector), and the color was developed by
diaminobenzidine tetrahydrochloride (DAB).
Analysis of Functional and Behavioral Outcome
Neurological status in mice was assessed according to a neuro-
logical grading score of increasing severity of deficit20: 0, no
observable deficit; 1, torso flexion to right; 2, spontaneous cir-
cling to right; 3, leaning/falling to right; 4, no spontaneous
movement. In rats an additive neurobehavioral scoring system
was used as described earlier21: body position (completely flat,
0 to upright position, 4); spontaneous activity (none, 0 to
repeated vigorous movement, 3); transfer arousal (coma, 0 to
extremely excited, 5); gait (absolute incapacity, 0 to normal, 3);
touch escape (none, 0 to extremely vigorous, 3), and positional
passivity (no struggle when held, 0 to maximal struggle, 4).
Cytokine Measurement
Sample processing and protein determination were performed
as described previously.19 In mice, plasma samples and saline-
perfused brain, liver, spleen, and lung homogenates were meas-
ured for tumor necrosis factor (TNF) a, RANTES, chemokine
(C-C motif ) ligand 2, chemokine (C-X-C motif ) ligand 1
(CXCL1), IL-6, IL-1b, IL-1a, IL-17a, interferon c, granulocyte
colony-stimulating factor (G-CSF), and IL-10 using CBA Flex
Sets (BD Biosciences, Oxford, UK) according to the manufac-
turers protocol, with FACSArray and LRSII flow cytometers
(BD Biosciences). Rat cytokines IL-1b, IL-6, CXCL1, and
TNFa in plasma, liver, spleen, and lung were measured with
DuoSet ELISA kits (R&D Systems, Abingdon, UK).
Flow Cytometry
Following Fc receptor blockade (antimouse CD16/CD32, clone
93; eBioscience, Hatfield, UK), cells were stained with cocktails
of selected antibodies: T cells (CD4-FITC, CD8-PE, CD3-APC,
CD45-PerCP-Cy5.5), B cells/dendritic cells (CD19-FITC,
CD11c-PE, MHCII-APC6CD45-PerCP-Cy5.5), B cells/granu-
locytes (CD19-FITC, Ly6G-PE, MHCII-APC, Ly6c-PerCP-
Cy5.5), granulocytes/monocytes (CD11b-FITC, Ly6G-PE, Ly6c-
PerCP-Cy5.5, CD115-APC), and platelets (CD61-FITC,
CD42d-PE, CD62P-APC). Antibodies were purchased from
eBioscience except for Ly6g-PE (1A8; BD Biosciences, Oxford,
UK). Cells were acquired on an LSRII flow cytometer (BD Bio-
sciences, Franklin Lake, NJ), and data were analyzed using FACS
Diva software (BD Biosciences, Franklin Lake, NJ).
Immunohistochemistry and Immunofluorescence
Immunostaining was performed as described earlier.16 For
immunohistochemistry, goat antimouse vascular cell adhesion
molecule (VCAM) 1 (1:250; R&D Systems) and rabbit anti-
Iba1 (1:1,000; Wako Chemicals, Neuss, Germany) primary
antibodies were used, and the staining was developed with
nickel DAB. For immunofluorescence, appropriate mixtures of
rat antimouse CD45 (1:200; AbD Serotec, Oxford, UK), goat
antimouse VCAM-1 (1:250; R&D Systems), rabbit anti-Iba1
(1:1,000; Wako Chemicals), goat anti–IL-1a (1:100; R&D
Systems), or rat anti-CD41 (1:100; BD Biosciences, Oxford,
UK) antibodies were used followed by the adequate
fluorochrome-conjugated Alexa 594 or Alexa 488 donkey anti-
sera (1:500; Invitrogen, Paisley, UK). Biotinylated tomato lec-
tin (10lg/ml, Sigma-Aldrich) was visualized with streptavidin–
Alexa 350 conjugate (Invitrogen). VCAM-positive blood ves-
sels were counted in 3 random fields of view for each serial
section (typically 8–10) in the cerebral cortex. Activated
microglia were counted in the striatum, cerebral cortex, and
hippocampus on 10 serial sections rostrocaudally (3–4 fields
per section). CD45-positive cells were counted in the caudal
lateral ventricle on 5 serial sections (starting at 21.58mm
from Bregma). The ventricular ependyma was visualized by
using VCAM immunofluorescence. Images were viewed on an
Olympus (Tokyo, Japan) BX51 upright microscope using 34,
310, 340, and 360 objectives and captured using a Cool-
snap ES camera (Photometrics, Tucson, AZ, USA) with Meta-
Vue Software (Molecular Devices, Winnersh, UK). Images
were processed and figures assembled in Adobe (San Jose, CA)
Photoshop CS6. Except for mild changes to brightness and
contrast applied uniformly across experimental groups, no
other modifications to digital images has been made.
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Staining of Aortae
Oil Red O staining was performed as described earlier.22 Plaque
density was calculated on Oil Red O–stained en face prepara-
tions of the aorta by light microscopy/image capture analysis to
determine the percentage lesion of the total area of the aorta.
For E-selectin staining, antigen retrieval was performed followed
by incubation with E-selectin antibody (1:25; Abcam, Cam-
bridge, UK), secondary biotinylated antibody (1:200), and
ABC / DAB for detection.
Quantitative Analysis and Statistics
Animals were randomized for the experiments by GraphPad
Random Number Generator (http://graphpad.com/quickcalcs/
randomN1.cfm). All quantitative analysis was performed under
blinded conditions. Group sizes were determined by power cal-
culation using DSS Research (https://www.dssresearch.com/)
and Stattol.net (http://www.stattools.net/SSizAOV_Pgm.php)
online resources, and based on results from previous studies
using the MCAo model in mice or rats with identical age, gen-
der, and genetic background (5% confidence level, 80% power,
and an estimated 20–40% standard deviation, resulting in
n5 5–8 for most experiments). Statistical power was also assessed
in individual experiments with S. pneumoniae. Data were analyzed
with Student t test (comparing 2 experimental groups, Prism 6.0;
GraphPad, La Jolla, CA), and 1-way or 2-way analysis of variance
(ANOVA), followed by Tukey and Bonferroni post hoc compari-
son, respectively (comparing 3 groups, Prism 6.0), or 3-way
ANOVA followed by Scheffe post hoc test (comparing 8 groups,
3 variables; Fig 1D, F; analyzed with StatView; SAS Institute,
Cary, NC). Neurological scores were analyzed with nonparametric
t test (Mann–Whitney test, 2 groups), or Kruskal–Wallis test fol-
lowed by Dunn multiple comparison (4 experimental groups).
p< 0.05 was considered statistically significant.
Results
S. Pneumoniae Infection Induces Systemic
Inflammation, Accelerates Atherosclerosis, and
Results in Cerebrovascular Inflammation
As atherosclerosis is the main risk factor for throm-
boembolism, and clinical data indicate an increased risk
of thrombotic events in patients with pneumonia,7–10 we
infected C57BL/6J and ApoE2/2 mice fed a chow or a
high-fat (Paigen) diet with increasing doses of a human
isolate, S. pneumoniae ATCC 49619, to mimic sustained
bacterial infection, and investigated cardio- and cerebro-
vascular responses. Infection caused a >2-fold increase in
the number of aortic plaques within 6 days in high fat-
fed WT mice, but had no additional effect on aortic pla-
que formation in ApoE2/2 mice, which already showed
advanced aortic plaques after 8 weeks of Paigen diet, as
also observed in our earlier studies (see Fig 1).22,23 The
atherogenic effect of infection was also confirmed in
aged, obese, and atherosclerotic corpulent rats based on
increased E-selectin expression by the aortic endothelium.
Analysis of peripheral cytokines showed elevated circulat-
ing IL-1a and IL-17 levels and increased IL-6 production
in the spleen in response to infection in mice. Athero-
genic diet also increased plasma IL-1a, but no additive
effect of infection was observed.
Next, we investigated whether infection caused
cerebrovascular inflammation. VCAM levels on the cere-
brovascular endothelium increased significantly in
response to infection, whereas atherogenic diet caused
vascular activation only in ApoE2/2 mice, as we reported
earlier (see Fig 1).22,23 There was no synergistic effect
between diet and infection. Microglial CD11b levels
were elevated in WT mice in response to infection, but
the number of Iba11 microglia was not altered. We
reported earlier that atherogenic diet induces leukocyte
accumulation in the choroid plexus that is most apparent
in atherosclerosis-prone ApoE2/2 mice.22 S. pneumoniae
infection significantly reduced (by 40%) diet-induced
accumulation of CD451 cells in the lateral ventricle,
indicating that infection-induced systemic responses
modify inflammatory changes in the brain. No acute car-
dio- or cerebrovascular events were observed in mice or
rats during the course of infection.
Preceding S. Pneumoniae Infection Exacerbates
Brain Injury and Potentiates BBB Breakdown in
Association with Age and Comorbidities
Sustained S. pneumoniae infection in young, healthy
C57BL/6J mice prior to experimental stroke resulted in a
significant (60%) exacerbation of brain injury induced by
cerebral ischemia and markedly impaired neurological
outcome 24 hours after reperfusion (Fig 2). Infected mice
showed a trend for reduced O2 saturation and had signifi-
cantly reduced pO2 levels in the blood before experimen-
tal stroke compared to uninfected mice, as expected in
animals with pneumonia, similarly to patients with com-
munity- or hospital-acquired pneumonia.24
To investigate the effect of S. pneumoniae infection
on stroke outcome in a comorbid rodent model, we
infected aged lean and corpulent (obese and atheroscler-
otic) rats prior to MCAo. Infection significantly exacer-
bated brain injury in both lean (by 55%) and corpulent
(by 90%) rats (see Fig 2). Aged, infected rats had mark-
edly increased BBB injury as identified by parenchymal
infiltration of plasma-derived IgG. Corpulent rats dis-
played significantly higher (by 40%) BBB breakdown in
response to infection compared to lean rats. Infection
worsened both behavioral outcome and sensory–motor
functions after experimental stroke, which paralleled
increased granulocyte recruitment in the ischemic hemi-
sphere (Fig 3). Splenic IL-1a and IL-6 levels were
increased after infection in corpulent, but not lean rats,
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FIGURE 1: Streptococcus pneumoniae infection facilitates aortic plaque formation and results in cerebrovascular inflammation.
(A) Aortic plaque number was assessed by en face Oil Red O staining of whole aortae in wild-type (WT) mice after 6 days of
infection with S. pneumoniae (n54–5). (B) Pulmonary S. pneumoniae infection increases aortic E-selectin expression in obese
and atherosclerotic corpulent rats. (C) Cytokine levels shown in the blood and the spleen after infection (n56–12). (D) Vascular
cell adhesion molecule (VCAM) immunohistochemistry reveals increased cerebrovascular activation in response to pulmonary S.
pneumoniae infection (n59–12). (E) Microglia display higher CD11b levels in the brain after infection as assessed in the stria-
tum (St), cerebral cortex (Cx), and hippocampus (Hc; n55). (F) Diet-induced accumulation of CD45-positive leukocytes in the
caudal lateral ventricle is reduced in ApoE2/2 mice in response to infection. $$$p<0.001 vs CC, AC, CP, ICC, IAC, and ICP;
#p<0.05 vs CC, AC, and CP; ##p<0.01 vs ICC, IAC, and ICP; *p<0.05, **p<0.01, ***p<0.001. Location of pictures in D and F
is shown on the schematic with red asterisks. AC5uninfected ApoE2/2 mice on chow diet; AP5uninfected ApoE2/2 mice on
Paigen diet; bv5blood vessels; CC5uninfected WT mice on chow diet; CP5uninfected WT mice on Paigen diet; DAPI540,6-
diamidino-2-phenylindole; IAC5 infected ApoE2/2 mice on chow diet; IAP5 infected ApoE2/2 mice on Paigen diet;
ICC5 infected WT mice on chow diet; ICP5 infected WT mice on Paigen diet; IL5 interleukin; n.d.5not detectable. Scale bars:
A, 5mm; B, 25lm; D, E, 50lm; F, 200lm.
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indicating that animals with chronic vascular disease
develop an exaggerated systemic inflammatory response
to S. pneumoniae after cerebral ischemia.
S. Pneumoniae Infection Causes Granulocytosis
and IL-1–Mediated Systemic Inflammatory
Response
Infected mice had elevated circulating granulocytes prior to
experimental stroke, which was associated with reduced B-
cell numbers in the blood (Fig 4). Bone marrow granulocyte
levels were also elevated, indicating that although the infec-
tion is localized to the lung, infection-induced systemic
inflammatory responses involve increased granulopoiesis in
the bone marrow and release of granulocytes into the circu-
lation. In addition to innate immune mechanisms, T cells
play a role in defense against S. pneumoniae infection.25–27
However, we found that infected mice had reduced CD81
T cells in the blood prior to cerebral ischemia.
Next, we investigated cytokine changes in the blood
and in peripheral organs after infection and cerebral ische-
mia. S. pneumoniae infection led to a 30- to 80-fold eleva-
tion in IL-1a and IL-1b levels in the lung, where the
infection was localized, 4 hours after MCAo, paralleled by
an increase in G-CSF, IL-6, and TNFa levels (20–30-fold,
Fig 5A). RANTES and TNFa levels were increased in the
liver in response to infection; IL-1a, IL-1b, G-CSF, peaked
4 hours after cerebral ischemia (see Fig 5B) in infected ani-
mals. No cytokine changes were detected in the spleen
between control and infected mice (not shown).
In infected mice, experimental stroke led to 2.5-
fold higher levels of MCP-1 and 5-fold higher levels of
KC in the brain compared to controls (see Fig 5C), two
key chemokines responsible for the recruitment of mono-
cytes and granulocytes to the brain.28,29
S. Pneumoniae Infection-Induced Brain Injury is
IL-1 Dependent
In mice, blocking IL-1 actions by IL-1Ra fully reversed the
increase in ischemic brain injury induced by infection and
restored impairment in sensory–motor performance (Fig
6). Infection induced a 3-fold increase in BBB injury,
which was reduced by 40% after IL-1Ra treatment. We
have reported previously that chronic infection preceding
stroke increases granulocyte numbers in the spleen, and
FIGURE 2: Streptococcus pneumoniae infection worsens brain injury after experimental stroke and induces granulocytosis. (A)
Mice were infected with increasing challenges of S. pneumoniae over 6 days prior to middle cerebral artery occlusion (MCAo)
that leads to an exacerbation of brain injury 24 hours after cerebral ischemia. (B) Cresyl violet (Nissl) staining shows the infarct
(dashed lines) in representative animals 24 hours after MCAo. (C) Neurological deficit is significantly impaired 24 hours after
cerebral ischemia in infected mice. (D) pO2 levels are lower in infected mice prior to MCAo. (E–G) Ischemic brain injury is exa-
cerbated in response to infection in aged lean (E) and corpulent (CP) rats (G). Brain injury is shown 24 hours after MCAo as
identified on cresyl violet–stained (Nissl; F) brain sections. (H) Infection prior to stroke augments blood–brain barrier (BBB)
injury that is more serious in corpulent rats. A–G, unpaired t test; H, two-way analysis of variance (ANOVA); *p<0.05,
**p<0.01; n58–9 mice, n57–9 rats. n.s.5not significant; PBS5phosphate-buffered saline. [Color figure can be viewed in the
online issue, which is available at www.annalsofneurology.org.]
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that granulocytes contribute to ischemic injury and BBB
breakdown mediated by systemic inflammation.16,30 IL-
1Ra significantly reduced granulocyte numbers in the
spleen (by >50%) and had similar effects on CD41 T cells
in the bone marrow, irrespective of infection status.
Similarly to mice, Wistar rats displayed significantly
elevated IL-1b levels (2-fold) in the liver in response to
infection, confirming the development of a systemic
inflammatory response (see Fig 6). Infection significantly
(by 40%) increased brain injury induced by cerebral
ischemia. IL-1Ra administration fully reversed the
infection-induced increase in brain injury and BBB
breakdown after cerebral ischemia, suggesting that
impaired outcome after stroke in response to S. pneumo-
nia is IL-1 dependent in both rodent models. IL-1Ra
treatment after cerebral ischemia also reversed brain
edema in infected rats, improved behavioral outcome,
and rescued motor performance.
S. Pneumoniae Infection Drives Brain Injury Via
Platelet-Dependent Inflammatory Responses
As infection could facilitate coagulatory processes,5 we
examined platelet aggregation in the brain. We found an
increased number of platelet aggregates in the area of the
infarct in infected mice after experimental stroke, and
this was also confirmed in the ipsilateral hemisphere of
both aged lean and corpulent rats in response to infec-
tion (Fig 7). Platelet accumulation was observed mostly
in small cerebral arteries, resulting in partial or complete
coverage of the vascular lumen, and was not affected by
IL-1Ra. Flow cytometric analysis confirmed increased
platelet activation in infected mice prior to MCAo as
identified by higher levels of P-selectin (CD62P) on
CD42d/CD61-positive circulating platelets. Blockade of
platelet GPIba (using a specific Fab fragment, which
does not induce depletion of platelets18) significantly
reduced infarct size and BBB injury, and improved
FIGURE 3: Streptococcus pneumoniae infection impairs functional outcome in aged rats in synergy with comorbidities following
cerebral ischemia. (A–D) Behavioral (A, B) and sensory–motor (C, D) outcome was assessed in infected (Pneumo) and uninfected
(control), 16-month-old lean rats (A, C) and obese, atherosclerotic corpulent (CP) rats (B, D) 24 hours after cerebral ischemia.
(E) Increased numbers of granulocytes were found in the ipsilateral hemisphere in infected rats 24 hours after middle cerebral
artery occlusion (as assessed by immunostaining with an antigranulocyte serum, SJC4). (F) Interleukin (IL) 1a and IL-6 levels
were measured by enzyme-linked immunosorbent assay in spleen homogenates. Two-way analysis of variance followed by Bon-
ferroni post hoc comparison, *p<0.05, **p<0.01, ***p<0.001; n57–9.
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neurological outcome in infected mice, but did not alter
platelet accumulation in the brain, suggesting an inflamma-
tory role for platelets. GPIba blockade did not facilitate
intracranial bleedings in infected mice. Only 2 mice receiv-
ing control IgG and 1 mouse receiving anti-GPIba Fab
showed minor hemorrhagic transformation (<0.1% of the
volume of the infarct). GPIba blockade did not mediate
protection against the small, primarily striatal injury in
uninfected mice.
Blockade of platelet GPIba reduced infection-
induced granulocyte recruitment in the brain by 50% (see
Fig 7). As both IL-1Ra and blockade of GPIba reversed
brain injury in infected mice, we further investigated
whether systemic inflammatory changes alter microglial
activation, which are the primary inflammatory cells in
the brain. Microglial (lectin1/Iba11) IL-1a was highly
expressed in the ipsilateral hemisphere in infected mice
after cerebral ischemia, which was significantly reduced
after platelet GPIba blockade. This reduction was most
apparent in the ipsilateral cerebral cortex (see Fig 6H).
Analysis of brain sections in infected mice also showed a
comparable reduction in cortical IL-1a–positive microglia
in response to IL-1Ra administration (see Fig 7J), indicat-
ing that IL-1– and platelet-dependent mechanisms con-
tribute to microglial inflammatory changes and brain
injury in response to infection after cerebral ischemia. We
have also assessed whether infection could contribute to
increased BBB injury, microglial IL-1a expression, or gran-
ulocyte recruitment independently of increased infarct size.
Mice displaying the smallest infarcts from the infection
group across different studies had comparable infarct size
to those showing the largest infarct volumes in the control
group (21.26 6mm2 vs 22.86 6.8mm2, respectively,
n5 5). Granulocyte numbers were not (56 1 cells/mm2
FIGURE 4: Streptococcus pneumoniae infection induces granulocytosis and a reduction in circulating B cells and CD81 T cells.
(A–C) Flow cytometric analysis indicates higher granulocyte (A) and lower MHCII1 B cell (C) numbers before middle cerebral
artery occlusion and 15 minutes after reperfusion in mice infected with S. pneumoniae (two-way analysis of variance [ANOVA]
followed by Bonferroni multiple comparison). (B) Representative dot blots showing granulocytes (P2 gate, Ly6G1, SSChigh) and
MHCII1 B cells (P3 gate, MHCII1 CD191). (D) Granulocytes are increased in the bone barrow after infection. (E) CD81 T cells
(CD31) are reduced in the circulation in infected mice. *p<0.05, **p<0.01, two-way ANOVA, followed by Bonferroni post hoc
comparison; n54–9 (number of individual cohorts has been displayed on the graphs). n.s.5not significant. [Color figure can
be viewed in the online issue, which is available at www.annalsofneurology.org.]
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vs 56 2 cells/mm2), but BBB injury volume
(22.96 3.8mm2 vs 13.86 4.8mm2, p< 0.01) and num-
ber of IL-1a–positive microglia (186 7 cells/mm2 vs
56 4 cells/mm2, p< 0.01) were significantly higher in
infected animals with even small infarcts compared to con-
trol mice after cerebral ischemia.
Discussion
We present evidence that sustained pulmonary S. pneu-
moniae infection, the most common cause of bacterial
community-acquired pneumonia, generates an IL-1–
mediated systemic inflammatory response involving
granulocytosis and platelet activation that accelerates
FIGURE 5: Streptococcus pneumoniae infection induces systemic interleukin (IL) 1 and exacerbates brain inflammation after cerebral
ischemia. (A) Infection (Pneumo) leads to elevated IL-1b and IL-1a levels after cerebral ischemia in the lung compared to uninfected
(Control) mice as well as increases in granulocyte colony-stimulating factor (G-CSF) and tumor necrosis factor (TNF) a. (B) IL-1a and
IL-1b levels in the liver before and after cerebral ischemia, accompanied by elevated G-CSF, TNFa, and RANTES levels. (C) Twenty-
four hours after middle cerebral artery occlusion, brain homogenates contain increased levels of proinflammatory chemokines KC
and MCP-1. *p<0.05 two-way analysis of variance followed by Bonferroni multiple comparison; n53 (0 hours) and n55 (4 hours
and 24 hours). [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
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FIGURE 6: Blockade of interleukin (IL) 1 actions by IL-1 receptor antagonist (IL-1Ra) reverses the effects of Streptococcus pneumo-
niae infection on outcome after cerebral ischemia in rodents. (A) The increase in infarct volume caused by infection is reversed after
IL-1Ra administration 1 hour after reperfusion, as measured on cresyl violet (Nissl)-stained brain sections. (B) Cresyl violet (Nissl) stain-
ing and immunohistochemical detection of plasma-derived immunoglobulin (Ig) G in the brain in uninfected (Control) and S. pneumo-
niae–infected (Pneumo) mice. (C) Blood–brain barrier (BBB) damage was measured by IgG staining. (D) Neurological outcome is
impaired after infection, which is fully reversed by IL-1Ra administration. (E) IL-1Ra administered to infected and uninfected mice 1
hour after reperfusion results in reduced splenic granulocyte and bone marrow T-cell numbers 24 hours after cerebral ischemia (two-
way analysis of variance [ANOVA] followed by Bonferroni post hoc comparison, n55–6). (F) IL-1b levels in the liver were measured
by enzyme-linked immunosorbent assay in control and infected Wistar rats after middle cerebral artery occlusion (MCAo). (G) IL-1Ra
administration 1 hour after reperfusion reverses infection-induced exacerbation of the ischemic brain injury in Wistar rats. (H) Cresyl
violet–stained, representative brain sections are shown in uninfected and infected mice with or without IL-1Ra. (I) BBB injury is
increased in response to infection, and this is reversed by IL-1Ra. (J) IL-1Ra reduced brain edema in infected rats after cerebral ische-
mia. (K) Behavioral outcome was assessed at various time points in control and infected rats before stroke (days 0, 4, and 7 postin-
fection) and 24 hours after MCAo (24 hours p.str., n56–7). (L) Neurological outcome is significantly improved in infected mice after
IL-1Ra treatment (n56–7; two-way ANOVA followed by Bonferroni post hoc comparison). *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001. veh.5 vehicle. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
FIGURE 7: Streptococcus pneumoniae infection exacerbates brain injury in mice after cerebral ischemia via platelet-dependent
responses. (A, i) Platelets in microvessels (lectin, blue) of the ipsilateral striatum and cortex have been identified by anti-CD41
(green) staining 24 hours after middle cerebral artery occlusion (MCAo) in mice. Arrowheads show intravascular platelet aggre-
gates; arrow shows the location of the inserts (upper right panel). Quantification shows the number of intravascular platelet
aggregates in the brain in mice (ii, control vs infected p<0.01, two-way analysis of variance [ANOVA]) and in lean and corpu-
lent (CP) rats (iii, p<0.01, two-way ANOVA followed by Bonferroni post hoc test). (B) Flow cytometric analysis of circulating
platelets identified by CD42d-PE indicates increased surface levels of CD62P (gate P5). (C) Increased infarct size in S.pneumo-
niae–infected mice (Pneumo) compared to uninfected mice (Control) is significantly reduced after blockade of glycoprotein
(GP) Iba with p0p/B Fab fragment, administered 1 hour after MCAo, compared to control immunoglobulin (Ig) G (C ab). (D)
Neurological scores indicate better functional recovery after GPIba blockade in infected mice. (E) Blood–brain barrier (BBB)
injury is reduced in infected mice after GPIba blockade. (F) Blockade of platelet GPIba does not increase the risk of intracranial
hemorrhage in infected mice as assessed on hematoxylin and eosin–stained brain sections (ipsilateral striatum is shown;
cc5 corpus callosum). (G) Granulocyte numbers (identified by an antigranulocyte serum, SJC4) were increased in the ipsilateral
striatum in infected mice 24 hours after MCAo. (H) Striatal granulocytes are reduced by >50% (not significant, p50.05) after
platelet GPIba blockade compared to control IgG (C ab). (I) Treatment with anti-GPIba antibody reduces microglial interleukin
(IL) 1a expression in the ipsilateral cerebral cortex (p<0.05, two-way ANOVA followed by Bonferroni post hoc comparison). (J)
IL-1 receptor antagonist (IL-1Ra) reduces microglial IL-1a expression in the ipsilateral cerebral cortex. Scale bars: A, 10lm; F,
500lm; I, 50lm; n56–7 (A, G, J), n55–8 (B), n55–7 (C, D, E, F, H, I). *p<0.05, **p<0.01, ***p<0.001. Cx5 cerebral cortex;
Hc5hippocampus; MFI5mean fluorescence intensity; St5 striatum; veh.5 vehicle.
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atherogenesis and leads to cerebrovascular inflammation.
S. pneumoniae–induced systemic inflammation preceding
an acute cerebrovascular event profoundly exacerbates
inflammation in the brain via IL-1– and platelet-
dependent mechanisms that augment microglial IL-1a
production and lead to increased neuronal injury.
Clinical data indicate that infection contributes to
the development of vascular disease, is a trigger for an
acute vascular event, and/or contributes to outcome once
an acute vascular event has occurred. In patients, infec-
tion could mediate all of these effects in both heart dis-
ease and stroke,5,8,10 although the mechanisms are not
known, and current experimental evidence is insufficient.
Chlamydia pneumoniae infection has been shown to
induce an unstable atherosclerotic plaque phenotype in
low-density lipoprotein receptor, ApoE double-knockout
mice.31 There is clinical evidence to show that S. pneu-
moniae contributes to atherogenesis,11,12 although the
efficacy of antibiotic treatment on heart disease is contro-
versial.32 However, no experimental studies have
addressed the role of sustained S. pneumoniae infection
in plaque growth or plaque rupture to date. We show
that systemic effects of infection induce inflammation in
distant vascular beds, and lead to vascular pathologies in
both the aorta and the brain, although the extent of the
response in individual mice was different. Our study was
not designed to specifically investigate plaque rupture,
hence it is not surprising that no acute cardio- or cere-
brovascular events were observed in infected, atheroscler-
otic rodents. In contrast, our data clearly indicate the
acceleration of atherogenesis by S. pneumoniae infection
in atherosclerosis-prone rodent models, arguing for a
contribution of S. pneumoniae to vascular disease.
To examine the effects of sustained and localized
pulmonary S. pneumoniae infection on systemic inflam-
matory changes and stroke outcome, we infected mice
intranasally with S. pneumoniae ATCC 49619 serotype
19F (Danish), a clinically relevant, human isolate.
Because major virulence factors such as pneumolysin are
conserved across all S. pneumoniae strains, we used mock
infection in control mice to account for any unexpected
effects caused by the inoculum in the lungs. In general,
serotype 19F isolates are associated with colonization of
mucosa,33 and are less commonly associated with invasive
disease (serotype 19F is included in the 7-valent conju-
gated pneumococcal polysaccharide vaccine PCV-7).
Lack of invasiveness of ATCC 49619 was also confirmed
in our experimental model. The infectious challenge was
titrated over 5 days to maximize the stimulation of the
immune system while minimizing the incidence of inva-
sive disease in the acute phase. Although in this model
the infection is localized to the lung, we found marked
systemic inflammatory changes in several organs, domi-
nated by the key proinflammatory cytokine, IL-1. It has
been shown that serious pulmonary infection can cause
multiorgan dysfunction and a high level of mortality.34
We developed our inoculation protocol to result in sus-
tained infection over a course of several days using inter-
mittent sublethal challenges, without causing major
weight loss, fever, behavioral alterations, or death.
In patients, infections preceding a stroke are associ-
ated with increased stroke risk and result in impaired
outcome, similarly to infections that develop post-
stroke.5,8,35,36 Our data clearly show that although pneu-
monia was associated with reduced pO2 levels (with O2
saturation unchanged) prior to stroke that could contrib-
ute to poor outcome, intervention against both IL-1 and
platelet GPIba reversed infection-induced cerebrovascular
inflammation, neuronal injury, and impaired functional
outcome, arguing for a major role of inflammation in
brain pathologies caused by systemic effects of pulmo-
nary S. pneumoniae infection. It is also possible that local
and/or systemic inflammation could compromise perfu-
sion and oxygen uptake/release in various organs includ-
ing the lung or the brain. However, mild hypoxia due to
lung inflammation was found to have no direct effect on
infarct size.37 Nevertheless, our results strongly suggest
that patients with stroke and pneumonia could benefit
substantially from anti-inflammatory therapies, such as
IL-1Ra. We investigated central and systemic inflamma-
tory mechanisms in detail to explain how IL-1 can medi-
ate injury after infection. As in our rodent model,
infection-induced neutrophil and platelet activation has
been documented in patients with pneumococcus-
induced lung infection.26,38 Granulocyte levels were
increased after infection and cerebral ischemia in the
brain, and were marginally reduced by GPIba blockade,
but not IL-1Ra, indicating that granulocyte responses
might not fully explain the effect of infection on brain
injury. Granulocyte numbers were not increased in
infected mice independently of infarct size either.
Although after IL-1–mediated cerebrovascular transmigra-
tion granulocytes acquire a neurotoxic phenotype, and
IL-1 actions can worsen injury in the brain via granulo-
cytes in vivo,30,39 increased numbers of parenchymal
granulocytes in the current experimental model might be
indirectly associated with infection status and thus bigger
infarcts. Nevertheless, systemic or perivascular granulo-
cyte responses might mediate brain injury independently
of the cells in the brain parenchyma, although this was
not tested experimentally in the present study. In con-
trast, both platelet intervention and IL-1Ra uniformly
reversed microglial IL-1a after cerebral ischemia in
infected mice, suggesting that altered microglial
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activation (which was evident even prior to infection)
could contribute to infection-induced inflammatory
responses. Similarly, increased BBB injury was evident in
infected mice with even smaller infarcts, supporting our
earlier observations that systemic inflammatory mecha-
nisms could mediate inflammation and injury in the
brain independently of changes in infarct size.40
Vascular activation after infection, and increased
platelet aggregation in infected mice after cerebral ische-
mia, suggested that inflammatory signals in the brain
might be mediated by activated platelets. According to a
recent study, S. pneumoniae can induce platelet aggrega-
tion in a strain-specific manner via toll-like receptor 2,
which is dependent on GPIIb/IIIa, but is not affected by
aspirin.41 In addition, our previous data indicated that a
chronic infection resulting in a systemic, Th1-polarized
immune response leads to the accumulation of platelets
in brain microvessels after cerebral ischemia,16 although
the functional role of platelets in the brain has not been
investigated earlier after infection. GPIba blockade did
not reduce microvascular platelet aggregates in the ische-
mic brain after S. pneumoniae infection, arguing for an
inflammatory role for platelet GPIba-mediated interac-
tions in augmenting cerebrovascular pathologies. We
reported recently that platelet-derived IL-1a can induce
cerebrovascular inflammation.42 Activated platelets release
IL-1 and/or IL-1–containing microparticles upon inter-
acting with the endothelium.42,43
We have demonstrated previously that peripheral
IL-1 administration exacerbates brain injury,30 and
inflammatory mechanisms reportedly contribute to cere-
bral ischemia even in the absence of systemic inflamma-
tion.28,29 Both GPIba blockade and IL-1Ra have been
shown to be protective in uninfected animals.17,18 How-
ever, due to the small cerebral injury (that mostly corre-
sponded to the core of the infarct) seen in uninfected
animals, we did not expect these interventions to signifi-
cantly reduce brain injury in control animals in the cur-
rent experimental model. Importantly, our present results
indicate that IL-1–dependent systemic inflammation and
pathologies in the central nervous system can develop in
response to sustained bacterial infection in vivo, and this
disease mechanism is central to the pathologies caused by
a clinically important gram-positive bacterium, S. pneu-
moniae. It is likely that such mechanisms could be
important in other vascular, noncommunicable diseases
as well, such as myocardial infarction, and liver or kidney
ischemia.
In conclusion, our data identify IL-1 as a key medi-
ator of infection-induced brain injury and indicate that
selective targeting of IL-1– and platelet-mediated mecha-
nisms could be therapeutically useful to prevent
infection-induced thromboinflammatory mechanisms,
which predispose to acute vascular events and lead to
profound impairment in outcome after stroke.
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